Company Description
Organon & Co. develops and delivers health solutions through a portfolio of prescription therapies and medical devices within women’s health in the United States and internationally.
Its women’s health portfolio comprises contraception and fertility brands, such as Nexplanon, a long-acting reversible contraceptive; NuvaRing, a monthly vaginal contraceptive ring; Cerazette, a daily pill used to prevent pregnancy; Marvelon, progestin and estrogen used as daily pills to prevent pregnancy; Follistim AQ, used to promote the development of multiple ovarian follicles in assisted reproduction technology procedures; Elonva, an ovarian follicle stimulant; Ganirelix Acetate Injection, an injectable antagonist; and Jada, for abnormal postpartum uterine bleeding or hemorrhage.
The company’s biosimilars portfolio consists of immunology products, such as Brenzys, Renflexis, and Hadlima; and two oncology products, including Ontruzant and Aybintio.
It offers cholesterol-modifying medicines under the Zetia, Ezetrol, Vytorin, Atozet, Inegy, Rosuzet, and Zocor brands; Cozaar and Hyzaar for the treatment of hypertension; respiratory products for treatments of control and prevent symptoms caused by asthma under the Singulair, Dulera, Zenhale, and Asmanex brand names; and Singulair, Nasonex, Clarinex, and Aerius for treating seasonal allergic rhinitis.
The company provides dermatology products under the Diprosone and Elocon brand; bone health portfolio, including Fosamax brand name; non-opioid pain management products under the Arcoxia, Diprospan, and Celestone brand names; Proscar for the treatment of symptomatic benign prostatic hyperplasia; and Propecia for the treatment of male pattern hair loss.
It sells its products to drug wholesalers and retailers, hospitals, pharmacies, clinics, government agencies, health maintenance organizations, pharmacy benefit managers, and other institutions.
The company was incorporated in 2020 and is headquartered in Jersey City, New Jersey.
| Country | United States |
| Founded | 1923 |
| Industry | Drug Manufacturers - General |
| Sector | Healthcare |
| Employees | 10,000 |
| CEO | Kevin Ali |
Contact Details
Address: 30 Hudson Street, Floor 33 Jersey City, New Jersey 07302 United States | |
| Phone | 551 430 6900 |
| Website | organon.com |
Stock Details
| Ticker Symbol | OGN |
| Exchange | NYSE |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001821825 |
| CUSIP Number | 68622V106 |
| ISIN Number | US68622V1061 |
| Employer ID | 46-4838035 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Kevin Ali | Chief Executive Officer and Director |
| Matthew M. Walsh C.F.A. | Executive Vice President and Chief Financial Officer |
| Kirke Weaver | Executive Vice President, General Counsel and Corporate Secretary |
| Susanne Gabriele Fiedler | Executive Vice President and Chief Commercial Officer |
| Joseph T. Morrissey Jr. | Executive Vice President and Head of Manufacturing and Supply |
| Rachel A. Stahler | Executive Vice President and Chief Information Officer |
| Jennifer Halchak | Head of Investor Relations |
| Susan O'Neal | Chief Ethics and Compliance Officer |
| Rebecca Lowell Edwards | Chief Communications Officer |
| Daniel Karp | Executive Vice President of Corporate Development |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Dec 23, 2024 | 8-K | Current Report |
| Dec 6, 2024 | 8-K | Current Report |
| Nov 5, 2024 | 8-K | Current Report |
| Nov 1, 2024 | 10-Q | Quarterly Report |
| Oct 31, 2024 | 8-K | Current Report |
| Sep 23, 2024 | 8-K | Current Report |
| Aug 7, 2024 | 10-Q | Quarterly Report |
| Aug 6, 2024 | 8-K | Current Report |
| Jun 25, 2024 | UPLOAD | Filing |
| Jun 6, 2024 | 8-K | Current Report |